Additionally, recent studies by Váraljai et al. on BRAFV600-mutated melanomas and their response to immune checkpoint inhibition, particularly dual therapy targeting both PD-1 and CTLA-4, have demonstrated that IL-17 supports the anti-tumor effects of combined ICI therapy [102]. This evidence concerns the gene IL17A and neoplasm.